Drugs / 177Lu-P17-088
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05603559 | Jan 2023 → Sep 2024 overdue | prostate carcinoma | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07562438 | Apr 2026 → Dec 2027 expected | prostate cancer | First Affiliated Hospital of Fujian Medical University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-P17-088 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05603559 ↗ |
| Known as | [177Lu]Lu-P17-088 | “Two novel PSMA-targeting radionuclide therapy agents, [177Lu]Lu-P17-087, and its albumin binder modified derivative, [177Lu]Lu-P17-088, were evaluated in metastatic...” PMID 38658392 ↗ Apr 2024 |
| Modality | Other / unclassified | “Two novel PSMA-targeting radionuclide therapy agents” PMID 38658392 ↗ Apr 2024 |
| Route | Intravenous | “administered intravenously once every 6-8 weeks (1 cycle) for 4 cycles” NCT07562438 ↗ |